Rivaban 2.5 is a 2.5 mg tablet made by Advanced Chemical Industries PLC. It contains rivaroxaban, an oral anticoagulant that helps reduce the chance of harmful blood clots forming.
There are 19 brands of Rivaroxaban listed in Bangladesh. 1 of them has a lower unit price than Rivaban 2.5. The lowest listed price is Rivadel 2.5 Tablet at ৳ 5 per unit.
What is Rivaban 2.5 Tablet?
Rivaban 2.5 is an oral anticoagulant tablet containing 2.5 mg of rivaroxaban. It works by blocking factor Xa, a substance in the blood clotting process, which lowers the formation of thrombin and helps reduce clot formation. Doctors prescribe it for adults after an acute coronary syndrome with raised cardiac biomarkers, alongside aspirin or aspirin with clopidogrel or ticlopidine. Because it affects clotting, bleeding is the main concern, and it should only be used under medical supervision. The dose and course are set by the doctor.
Uses of Rivaban 2.5
Rivaban 2.5 is used in adults after an acute coronary syndrome where cardiac biomarkers are raised, to help prevent atherothrombotic events. It is given together with aspirin alone, or with aspirin plus clopidogrel or ticlopidine. It is an oral anticoagulant and is not meant for self-treatment. Ask the doctor whether it suits your condition and what other medicines you need to take with it.
How to use Rivaban 2.5
Rivaban 2.5 is a tablet taken by mouth. The doctor decides the dose, how often to take it, and how long the course lasts, and also which other medicines are taken alongside it. Follow the doctor's instructions exactly and do not change the dose yourself. If you miss a dose or are unsure about anything, ask your doctor or pharmacist rather than adjusting it on your own.
Side effects of Rivaban 2.5
The most common side effect of rivaroxaban is an increased chance of bleeding. Spinal or epidural hematoma can occur, and there is an increased risk of stroke after stopping the medicine in people with nonvalvular atrial fibrillation. Tell your doctor promptly about any unusual or prolonged bleeding. Ask your doctor or pharmacist about any other effects you notice while taking Rivaban 2.5.
Safety and precautions
Rivaban 2.5 is not for people with a known allergy to rivaroxaban or any ingredient of the tablet, or with active pathological bleeding. Stopping it early without other adequate anticoagulation raises the risk of thrombotic events. Bleeding risk may be higher with bleeding disorders, uncontrolled severe high blood pressure, certain gastrointestinal diseases, vascular retinopathy, bronchiectasis, or a history of pulmonary bleeding. It is a pregnancy category C drug; safety in pregnancy and breastfeeding has not been established, so ask your doctor first.
Frequently asked questions
Is Rivaban 2.5 safe during pregnancy or breastfeeding?
Rivaroxaban is a pregnancy category C drug, and there are no adequate or well-controlled studies in pregnant women; dosing for pregnant women has not been established. It is not known whether it passes into human milk, and safety in breastfeeding women has not been established. Ask your doctor before use.
What is Rivaban 2.5 used for and what kind of medicine is it?
It is an oral anticoagulant tablet containing 2.5 mg rivaroxaban. It is used in adults after an acute coronary syndrome with raised cardiac biomarkers to help prevent atherothrombotic events, taken with aspirin alone or with aspirin plus clopidogrel or ticlopidine. Your doctor will confirm whether it is suitable for you.
How should Rivaban 2.5 be taken?
It is a tablet taken by mouth. The doctor decides the dose, how often it is taken, and how long the course lasts, as well as which other medicines you take with it. Follow the doctor's instructions exactly and do not change the dose yourself. Ask your doctor or pharmacist if anything is unclear.
What should I tell my doctor before taking Rivaban 2.5?
Tell your doctor about any allergy to rivaroxaban or tablet ingredients, active bleeding, bleeding disorders, uncontrolled severe high blood pressure, gastrointestinal disease, vascular retinopathy, bronchiectasis, or a history of pulmonary bleeding. Also mention all other medicines you take, since some can raise bleeding risk or affect how the medicine works.
For the prevention of atherothrombotic events in adult patients after an Acute Coronary Syndrome (ACS) with elevated cardiac biomarkers (Troponin or CK-MB). It is co-administered with Aspirin alone or with Aspirin plus Clopidogrel orTidopidine.
For the prevention of atherothrombotic events in adult patients after an Acute Coronary Syndrome (ACS) with elevated cardiac biomarkers (Troponin or CK-MB). It is co-administered with Aspirin alone or with Aspirin plus Clopidogrel orTidopidine.
Rivaroxaban 10-20 mg:
To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
Deep vein thrombosis (DVT) & pulmonary embolism (PE) and reduction in the risk of recurrence of DVT and of PE
For the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery
Pharmacology
Rivaroxaban is a highly selective direct factor Xa inhibitor. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibits thrombin formation. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated.
Dosage & Administration
Rivaroxaban 2.5 mg:
The recommended dose: 2.5 mg twice daily. Patients should also take a daily dose of 75-100 mg Aspirin or a daily dose of 75-100 mg Aspirin in addition to either a daily dose of 75 mg clopidogrel or a standard daily dose of ticlopidine.
Rivaroxaban 10-20 mg:
Nonvalvular Atrial Fibrillation: For patients with Creatinin Clearance >50 mL/min: 20 mg orally, once daily with the evening meal. For patients with Creatinin Clearance 15-50 ml/min: 15 mg orally, once daily with the evening meal.
Treatment of DVT & PE: 15 mg orally twice daily with food for the first 21 days for the initial treatment of acute DVT or PE. After the initial treatment period, 20 mg orally once daily with food for the remaining treatment.
Prevention in the risk of recurrence of DVT and of PE: 20 mg once daily with food.
Prophylaxis of DVT following Hip replacement surgery: 10 mg once daily for 35 days.
Prophylaxis of DVT following knee replacement surgery: 10 mg once daily for 12 days.
May be taken with or without food.
Interaction
Concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin, fluconazole, diltiazem, verapamil, dronedarone) increases in Rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation), that’s why should be avoided. Co-administration of Rivaroxaban with a combined P-gp and strong CYP3A4 inducer (e.g., rifampicin, phenytoin, carbamazepine) decreases the efficacy of Rivaroxaban and also should be avoided. The concomitant use of other drugs like anti-platelet agents, heparin, fibrinolytic therapy, NSAIDs may cause an increased risk of bleeding.
Contraindications
It is contraindicated in patients with known hypersensitivity of Rivaroxaban or any of the excipients of the product. It is also contraindicated in patients with active pathological bleeding.
Side Effects
The most common side effects of Rivaroxaban have increased chance of bleeding, spinal or epidural hematoma and increased risk of stroke after discontinuation in nonvalvular atrial fibrillation.
Pregnancy & Lactation
Rivaroxaban is a pregnancy category C drug. There are no adequate or well-controlled studies of Rivaroxaban in pregnant women, and dosing for pregnant women has not been established. It is not known if Rivaroxaban is excreted in human milk. The safety and efficacy of Rivaroxaban has not been established in breastfeeding women.
Precautions & Warnings
Early discontinuation of Rivaroxaban, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. Rivaroxaban increases the risk of bleeding that can be fatal in presence of following risk factors- bleeding disorders, uncontrolled severe arterial hypertension, gastrointestinal disease (e.g., inflammatory bowel disease, oesophagitis, gastritis and gastroesophageal reflux disease), vascular retinopathy, bronchiectasis, history of pulmonary bleeding. Signs or symptoms of neurological impairment should be monitored in case of neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture as epidural or spinal hematoma can occur. Rivaroxaban is not recommended in patients with pulmonary embolism who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy.
Overdose Effects
Overdose of Rivaroxaban may lead to hemorrhage. Rivaroxaban systemic exposure is not further increased at single doses >50 mg due to limited absorption. A specific antidote for Rivaroxaban is not available. The use of activated charcoal to reduce absorption in case of Rivaroxaban overdose may be considered. Partial reversal of laboratory anticoagulation parameters may be achieved with use of plasma products.
Storage Conditions
Store in a cool (below 30°C) & dry place protected from light. Keep away from the reach of children.
Alternative brands of Rivaroxaban
Other brands with the same generic name, cheapest first.